References
- Rosenwald A, Wright G, Chan W C, Connors J M, Campo E, Fisher R I, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937–1947
- Shipp M A, Ross K N, Tamayo P, Weng A P, Kutok J L, Aguiar R C, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8: 68–74
- Ting J P, Zhu X S. Class II MHC genes: a model gene regulatory system with great biologic consequences. Microbes Infect 1999; 1: 855–861
- Rimsza L M, Roberts R A, Miller T P, Unger J M, LeBlanc M, Braziel R M, et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 2004; 103: 4251–4258
- List A F, Spier C M, Miller T P, Grogan T M. Deficient tumor-infiltrating T-lymphocyte response in malignant lymphoma: relationship to HLA expression and host immunocompetence. Leukemia 1993; 7: 398–403
- Miller T P, Lippman S M, Spier C M, Slymen D J, Grogan T M. HLA-DR (Ia) immune phenotype predicts outcome for patients with diffuse large cell lymphoma. J Clin Invest 1988; 82: 370–372
- Stopeck A T, Gessner A, Miller T P, Hersh E M, Johnson C S, Cui H, et al. Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma. Clin Cancer Res 2000; 6: 3904–3909
- O'Keane J C, Mack C, Lynch E, Harrington D, Neiman R S. Prognostic correlation of HLA-DR expression in large cell lymphoma as determined by LN3 antibody staining. An Eastern Cooperative Oncology Group (ECOG) study. Cancer 1990; 66: 1147–1153
- Rimsza L M, Roberts R A, Campo E, Grogan T M, Bea S, Salaverria I, et al. Loss of major histocompatibility class II expression in non-immune privileged site diffuse large B cell lymphoma is highly coordinated and not due to chromosomal deletions. Blood 2006; 107: 1101–1107
- Klimo P, Connors J M. Macop-B Chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Int Med 1985; 102: 596–602
- Gatter J C, Warnke R A. Diffuse large B cell lymphoma. Pathology and Genetics, Tumours of Haematopoietic and Lymphoid Tissues, E S Jaffe, N L Harris, H Stein, J W Vardiman. IARC Press, LyonFrance 2001; 171–174
- Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
- Shipp M A, Harrington D P, Anderson J R, Armitage J O, Bonadonna G, Brittinger G, et al. A predictive model for aggressive non-Hodgkins-lymphoma. N Engl J Med 1993; 329: 987–994
- Cox D R. Regression models and life tables. J Roy Stat Soc B 1972; B34: 187–220
- Alizadeh A A, Eisen M B, Davis R E, Ma C, Lossos I S, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503–511
- Hans C P, Weisenburger D D, Greiner T C, Gascoyne R D, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275–282
- Jordanova E S, Riemersma S A, Philippo K, Giphart-Gassler M, Schuuring E, Kluin P M. Hemizygous deletions in the HLA region account for loss of heterozygosity in the majority of diffuse large B-cell lymphomas of the testis and the central nervous system. Genes Chrom Cancer 2002; 35: 38–48
- Riemersma S A, Jordanova E S, Schop R F, Philippo K, Looijenga L H, Schuuring E, et al. Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. Blood 2000; 96: 3569–3577